DAVID EDUARDO GARZA
Allopathic & Osteopathic Physicians|Internal Medicine PLANO, TX NPI 1043380306
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine TX ABBVIE INC. All categories
General Payments — all program years on this page
$8,569.67
- Category: General Payments
- Program years: PY2018–2024
- Record count: 554
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,192.30 across 65 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,192.30 | 65 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $237.67 | 20 |
| DEXCOM, INC. | $150.11 | 3 |
| Abbott Laboratories | $94.16 | 5 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $86.94 | 4 |
| Novo Nordisk AS | $71.36 | 4 |
| Exact Sciences Corporation | $70.55 | 3 |
| PFIZER INC. | $64.86 | 3 |
| Astellas Pharma US Inc | $53.03 | 3 |
| Azurity Pharmaceuticals, Inc. | $38.45 | 2 |
| Phathom Pharmaceuticals, Inc. | $37.17 | 2 |
| Lilly USA, LLC | $36.84 | 2 |
| GlaxoSmithKline, LLC. | $32.95 | 2 |
| Relypsa, Inc. | $28.63 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.04 | 1 |
| Philips Electronics North America Corporation | $20.62 | 1 |
| Amgen Inc. | $17.70 | 1 |
| Ultragenyx Pharmaceutical Inc. | $17.35 | 1 |
| Siemens Medical Solutions USA, Inc. | $17.31 | 1 |
| Seqirus USA Inc | $16.91 | 1 |
| AIMMUNE THERAPEUTICS, INC. | $16.67 | 1 |
| Janssen Pharmaceuticals, Inc | $15.89 | 1 |
| Merck Sharp & Dohme Corporation | $14.98 | 1 |
| Esperion Therapeutics, Inc. | $14.87 | 1 |
| Acerta Pharma LLC | $13.24 | 1 |
By program year
Records — PY2024 (65)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.